Skip to main content

We have several areas of research interest broadly in the area of immunomodulation using micro/nanoparticles and other carrier systems. Check out Dr. Ainslie’s funding at GrantTome.com (link).

FORMULATION OF HOST-DIRECTED AND OTHER THERAPEUTIC COMPOUNDS

We apply both polymeric and liposomal carriers to delivery immunomodulatory drugs and/or therapeutics to phagocytic and other cells. A large focus of this work is on host-directed therapeutics which manipulate the mammalian host cell environment to make it less hospitable for the pathogen inside it, in an effort to reduce the emergence of drug resistance in that pathogen as well as potentially sensitize the pathogen to conventional antibiotics. We have a review on formulation of host-directed therapies (Varma et al. 2020).
IMPROVED FORMULATION OF VACCINES

We can significantly improve cellular vaccine response to safe subunit (e.g. protein) based vaccines by using Acetalated Dextran (Ac-DEX), an acid-sensitive, pH neutral, and tunable degrading biopolymer. We also focus on scalable methods of creating efficacious and safe vaccines. We have a review on Ac-DEX that highlights much of our vaccine work (Bachelder et al. 2017).
ANTIGEN SPECIFIC TREATMENT OF AUTOIMMUNE DISEASES

In the same way that vaccines specifically prime the immune system towards a disease, we aim to turn-down the autoimmune response in an anitgen specific manner, rather than the blanket suppression used currently to treat autoimmune diseases. We have a review on micro and nanoparticle formulations for antigen specific therapy (Chen et al. 2015)
SCAFFOLDS FOR CONTROLLED RELEASE OF DRUG AND TISSUE ENGINEERING

We have formulated Ac-DEX into electrospun scaffolds and applied them for interstitial drug delivery to treat gliblastoma. Also, in collaboration with Dr. Shawn Hingtgen, we have developed scaffolds for stem cell delivery.